Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Recent Patents on Anti-Cancer Drug Discovery is Scopus-indexed (Q2, CiteScore 5.6), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Bentham Science Publishers.
Checked against the index lists dated .
ISSN 1574-8928Verify ISSN ↗2212-3970Verify ISSN ↗
Publisher: Bentham Science Publishers
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology (medical) | 79 / 278 | 71st | Q2 |
| Oncology | 129 / 428 | 69th | Q2 |
| Drug Discovery | 66 / 161 | 59th | Q2 |
| Cancer Research | 106 / 233 | 54th | Q2 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2006–present, best quartile Q2, CiteScore 5.6.
Recent Patents on Anti-Cancer Drug Discovery is Q2 in Pharmacology (medical) (rank 79 of 278), Q2 in Oncology (rank 129 of 428) and Q2 in Drug Discovery (rank 66 of 161), by CiteScore 2025. It is ranked in 4 subject areas in all.
Recent Patents on Anti-Cancer Drug Discovery is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 5.6, which places it in quartile Q2 at the 71st percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.635, quartile Q2, with an H-index of 55.
Recent Patents on Anti-Cancer Drug Discovery is published by Bentham Science Publishers. Its print ISSN is 1574-8928 and its online ISSN is 2212-3970.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Recent Patents on Anti-Cancer Drug Discovery has an h-index of 59 and a 2-year mean of 1.77 citations per paper (OpenAlex). Its Scopus CiteScore is 5.6, quartile Q2. On 2-year citations it ranks #140 of 271 Scopus journals in Pharmacology (medical).
Recent Patents on Anti-Cancer Drug Discovery published 42 papers in 2025; its busiest recent year was 2021 with 87. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 90 research articles (2024–2026), authors are most often from China (70.4%), India (10.4%) and United States (3.7%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 1 retracted paper is recorded (1.1 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.